Skip to content
  • Career
  • Support
  • Contact Us
Menu
  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Search
Close
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get a Quote
    • Get Set Up
  • News & Events
    • News
    • Events
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us
  • All posts

AMRA Medical’s MRI data provide a unique opportunity for Pfizer’s GWAS

  • February 14, 2022

LINKÖPING, Sweden; February 14, 2022—One of the goals of AMRA’s collaboration with Pfizer and UK Biobank is to help identify and validate noninvasive biomarkers to assess liver fat, which traditionally must be measured via liver biopsy. Pfizer recently used AMRA’s magnetic resonance imaging (MRI) liver proton density fat fraction (PDFF) biomarker in a genome-wide association study (GWAS)to validate genetic loci associated with liver fat percentage. These genetic markers may potentially expand the toolkit of researchers seeking to treat patients with metabolic diseases.

Pfizer’s recent GWAS showed several genomic loci significantly associated with liver fat percentage, which was quantified by AMRA’s protocol for MRI PDFF — a quantitative imaging biomarker that enables accurate and reproducible assessment of liver fat. The genomic hits included two fatty liver disease-associated genes, PNPLA3 and TM6SF2; metabolism-related genes MARC1 and GPAM; glucokinase inhibitor GCKR; and several other genes. These findings show that AMRA’s MRI protocols have the potential to equip genetic researchers with accurate and precise biomarkers for identifying novel disease associations and exploring disease-related pathways.

AMRA and Pfizer are currently working to analyze the body composition of up to 100,000 individuals from the UK Biobank biomedical database to generate detailed data in support of target discovery and validation — to aid scientific and clinical research into a range of complex diseases and overall metabolic health. A significant contribution to the collection is being provided by AMRA, a ground-breaking digital health company and global leader in body composition analysis that has quantified the distribution of liver fat in over 40,000 imaged individuals.

Learn more about AMRA’s research services and capabilities.

About AMRA Medical

AMRA is a digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition analysis, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI scan.

Learn more about UK Biobank

UK Biobank is a large-scale biomedical database and research resource containing anonymised genetic, lifestyle and health information from half a million UK participants. UK Biobank’s database, which includes blood samples, heart and brain scans and genetic data of the volunteer participants, is globally accessible to approved researchers who are undertaking health-related research that’s in the public interest.

UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the UK. With their consent, they provided detailed information about their lifestyle, physical measures and had blood, urine and saliva samples collected and stored for future analysis.
UK Biobank’s research resource is a major contributor in the advancement of modern medicine and treatment, enabling better understanding of the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases and stroke. Since the UK Biobank resource was opened for research use in April 2012, over 28,000 researchers from +90 countries have been approved to use it and more than 3,000 peer-reviewed papers that used the resource have now been published.

UK Biobank is generously supported by its founding funders the UK Medical Research Council (MRC) and Wellcome, as well as the British Heart Foundation, Cancer Research UK, the National Institute of Health Research (NIHR), UK Research and Innovation (UKRI). The organisation has over 180 dedicated members of staff, based in multiple locations across the UK.

You can find out more about UK Biobank at http://www.ukbiobank.ac.uk

  • All posts
Research Services
Follow us
Linkedin Twitter Facebook

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support
  • Data Privacy Policy
  • Cookie Policy
  • Data Privacy Policy
  • Cookie Policy

Newsletter

    © 2023 AMRA Medical AB

    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}
    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}